Trial intelligence / Profile preview

Phase 2 neoadjuvant zanidatamab plus chemotherapy in HER2-positive breast cancer

2025-523204-68-00Phase 2Authorised

Sponsor: Jazz Pharmaceuticals plc
Start: Mar 2026
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 4

Overview

Phase 2, randomised, open-label trial of zanidatamab in breast cancer (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Pathologic complete response rate. Planned start Mar 2026; status: authorised.

Drugs

zanidatamab

Conditions

breast cancer

Beyond the preview

Go deeper on 2025-523204-68-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-523204-68-00.